Published in PLoS One on March 03, 2016
Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C | NCT02545335
Quantification of Side Effects During Hepatitis C Therapy | NCT02545400
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2013) 4.46
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol (1996) 2.24
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology (2007) 2.08
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother (2008) 1.56
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother (2010) 1.49
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol (2012) 1.17
Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res (2008) 1.14
Neutrophil-derived serine proteases modulate innate immune responses. Front Biosci (Landmark Ed) (2009) 1.02
Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin. J Viral Hepat (2013) 0.96
Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr (2009) 0.96
Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther (2013) 0.93
Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol (2008) 0.93
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur J Gastroenterol Hepatol (2014) 0.90
The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur J Clin Nutr (2012) 0.89
The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. J Hepatol (2014) 0.84
Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf (2014) 0.82
Elastase activity in pancreatic juice and plasma of the dog. Arch Surg (1972) 0.81
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One (2014) 0.80
RANTES, TNF-α, oxidative stress, and hematological abnormalities in hepatitis C virus infection. J Investig Med (2012) 0.80
Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. Ann Hepatol (2014) 0.77
Tuberculous sepsis during antiviral HCV triple therapy. J Hepatol (2013) 0.77
Knowledge and attitude of ICU nurses, students and patients towards the Austrian organ donation law. BMC Med Ethics (2013) 1.57
Extracorporeal liver support devices for listed patients. Liver Transpl (2016) 0.79
Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redoxbiology and performance in aerobically trained subjects. J Int Soc Sports Nutr (2015) 0.78
Mode of renal replacement therapy determines endotoxemia and neutrophil dysfunction in chronic kidney disease. Sci Rep (2016) 0.75
Serum bile acids in liver cirrhosis promote neutrophil dysfunction. Clin Transl Med (2022) 0.75